Supporting information
Additional supporting information may be found online in the Supporting Information section at the end of the article.
Table S1. Clinico-pathological characteristics of patients with recurrent or persistent disease (N = 65)
Table S2. Adverse effects and grades in ovarian/tubal/peritoneal patients treated with bevacizumab plus chemotherapy (N = 142).
Figure S1. Study flow chart
(A) Cohort 1 patients underwent first-line paclitaxel-carboplatin chemotherapy with or without bevacizumab (BEV).(B) Cohort 2 patients with relapsed or persistent disease treated with BEV ± chemotherapy. Patients were also categorized as groups with progression-free interval (PFI) <6 and ≥6 m.
Figure S2. Progression-free and overall survival between paclitaxel-carboplatin chemotherapy (Chemo) with and without bevacizumab (BEV) in stage III–IV patients undergoing first-line therapy were tested using the log-rank test (A) in the progression-free interval (PFI) ≥6 m subgroup and (B) in the PFI <6 m subgroup.
Figure S3. Progression-free and overall survival curves stratified by the use of bevacizumab in subgroups of serous and clear cell histology in an early and advanced stage, tested by the log-rank test. (A) Early-stage clear cell carcinoma group, (B)early-stage serous carcinoma group, (C) advanced-stage clear cell carcinoma group, and (D) advanced-stage serous carcinoma group.